Targeted protein degradation is a promising area in the discovery and development of
innovative therapeutics. Molecular glues mediate proximity-induced protein degradation and …

Molecular glue degraders are small, drug-like compounds that induce interactions between
an E3 ubiquitin ligase and a target, which result in ubiquitination and subsequent …

Immunotherapy has received tremendous attention for tumor treatment, but the efficacy is
greatly hindered by insufficient tumor‐infiltration of immune cells and immunosuppressive …

Supramolecular self‐assembling peptide systems are attracting increasing interest in the
field of cancer theranostics. Additionally, transformation of the immunologically cold tumor …

Whereas the PROTAC approach to target protein degradation greatly benefits from rational
design, the discovery of small-molecule degraders relies mostly on phenotypic screening …

Abstract Target Protein Degradation TPD is a new avenue and revolutionary for therapeutics
because redefining the principles of classical drug discovery and guided by event-based …

Targeted protein degradation has exploded over the past several years due to preclinical
and early clinical therapeutic success of numerous compounds, and the emergence of new …

Thalidomide and its analogs are molecular glues (MGs) that lead to targeted ubiquitination
and degradation of key cancer proteins via the cereblon (CRBN) E3 ligase. Here, we …

The development and application of traditional drugs represented by small molecule
chemical drugs and biological agents, especially inhibitors, have become the mainstream …

Epigenomic alterations can give rise to various tumor-promoting properties, including
therapeutic resistance of cancer cells. Here, we identify an lncRNA, BDNF-AS, whose …